Kiniksa Pharmaceuticals Headquarters
Looking for information about Kiniksa Pharmaceuticals Headquarters? The links below have collected all the necessary data.
Kiniksa Pharmaceuticals A Global and Innovative ...
- https://www.kiniksa.com/
- Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
Stay Informed Kiniksa Pharmaceuticals
- https://www.kiniksa.com/stay-informed
- Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
Clinical Trials Kiniksa Pharmaceuticals
- https://www.kiniksa.com/clinical-trials
- Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
Kiniksa Outlines Next Steps for the Development of ...
- https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-outlines-next-steps-development-mavrilimumab
- Jun 08, 2021 · HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today outlined next steps for the development of mavrilimumab, an investigational fully-human monoclonal antibody that …
Press Release Details - Kiniksa Pharmaceuticals
- https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-results-mavrilimumab-phase-2-trial
- Apr 12, 2021 · HAMILTON, Bermuda, April 12, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the Phase 2 portion of the Phase 2/3 trial of mavrilimumab in non-mechanically-ventilated patients (Cohort 1) with severe …
Have you found Kiniksa Pharmaceuticals Headquarters information?
On our site you can find many other information about headquarters of any company. Research information about other companies.